Cargando…

Screening‐based identification of xanthone as a novel NLRP3 inflammasome inhibitor via metabolic reprogramming

Detalles Bibliográficos
Autores principales:	Cui, Wenyu, Chen, Sheng, Chi, Zhexu, Guo, Xingchen, Zhang, Xiaobo, Zhong, Yueyang, Han, Haijie, Yao, Ke
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Letter to Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8288006/ https://www.ncbi.nlm.nih.gov/pubmed/34323410 http://dx.doi.org/10.1002/ctm2.496

Ejemplares similares

Priming of NLRP3 inflammasome activation by Msn kinase MINK1 in macrophages
por: Zhu, Kaixiang, et al.
Publicado: (2021)

NLRP3 inflammasome activation in response to metals
por: Huang, Wanyi, et al.
Publicado: (2023)

Design, synthesis, and screening of sulfonylurea-derived NLRP3 inflammasome inhibitors
por: Kulkarni, Amol A., et al.
Publicado: (2019)

Pharmacological Inhibitors of the NLRP3 Inflammasome
por: Zahid, Ayesha, et al.
Publicado: (2019)

Reprogramming Macrophage Metabolism and its Effect on NLRP3 Inflammasome Activation in Sepsis
por: Luo, Ruiheng, et al.
Publicado: (2022)

Boron-Based Inhibitors of the NLRP3 Inflammasome
por: Baldwin, Alex G., et al.
Publicado: (2017)

NLRP3 Inflammasome Inhibitors in Cardiovascular Diseases
por: Mezzaroma, Eleonora, et al.
Publicado: (2021)

Identification of a novel orally bioavailable NLRP3 inflammasome inhibitor
por: Agarwal, Sameer, et al.
Publicado: (2020)

Ocular Wnt/β-Catenin Pathway Inhibitor XAV939-Loaded Liposomes for Treating Alkali-Burned Corneal Wound and Neovascularization
por: Zhong, Yueyang, et al.
Publicado: (2021)

NLRP3 inflammasome and its inhibitors: a review
por: Shao, Bo-Zong, et al.
Publicado: (2015)

Inhibition of the NLRP3 inflammasome by HSP90 inhibitors
por: Nizami, Sohaib, et al.
Publicado: (2020)

A Selective Review and Virtual Screening Analysis of Natural Product Inhibitors of the NLRP3 Inflammasome
por: El-Sayed, Sherihan, et al.
Publicado: (2022)

The NLRP6 inflammasome
por: Zheng, Danping, et al.
Publicado: (2020)

NLRP3 inflammasome in cognitive impairment and pharmacological properties of its inhibitors
por: Xu, Yi, et al.
Publicado: (2023)

Design, Synthesis and Evaluation of Oxazaborine Inhibitors of the NLRP3 Inflammasome
por: Baldwin, Alex G., et al.
Publicado: (2018)

Promise of the NLRP3 Inflammasome Inhibitors in In Vivo Disease Models
por: Das, Biswadeep, et al.
Publicado: (2021)

The mechanism of NLRP3 inflammasome activation and its pharmacological inhibitors
por: Zhan, Xiaoyan, et al.
Publicado: (2023)

Chalcone: A potential scaffold for NLRP3 inflammasome inhibitors
por: Thapa, Pritam, et al.
Publicado: (2023)

Gender Differences of NLRP1 Inflammasome in Mouse Model of Alzheimer's Disease
por: Zhang, Jinghang, et al.
Publicado: (2020)

Structure–Activity Relationship of Xanthones as Inhibitors of Xanthine Oxidase
por: Zhou, Ling-Yun, et al.
Publicado: (2018)

A novel dual NLRP1 and NLRP3 inflammasome inhibitor for the treatment of inflammatory diseases
por: Docherty, Callum AH, et al.
Publicado: (2023)

The Significance of NLRP Inflammasome in Neuropsychiatric Disorders
por: Shen, Yao, et al.
Publicado: (2022)

A phenotypic high-content, high-throughput screen identifies inhibitors of NLRP3 inflammasome activation
por: Nizami, Sohaib, et al.
Publicado: (2021)

Correlation Between the NLRP3 Inflammasome and the Prognosis of Patients With LSCC
por: Xue, Yi, et al.
Publicado: (2019)

Identification of ethyl pyruvate as a NLRP3 inflammasome inhibitor that preserves mitochondrial integrity
por: Li, Sujun, et al.
Publicado: (2018)

Enhanced Autolysosomal Function Ameliorates the Inflammatory Response Mediated by the NLRP3 Inflammasome in Alzheimer’s Disease
por: Zhou, Wen, et al.
Publicado: (2021)

Inhibiting the NLRP3 Inflammasome
por: El-Sharkawy, Lina Y., et al.
Publicado: (2020)

Modulatory Mechanisms of the NLRP3 Inflammasomes in Diabetes
por: Ding, Sujuan, et al.
Publicado: (2019)

Recent advances in the mechanisms of NLRP3 inflammasome activation and its inhibitors
por: Yang, Yang, et al.
Publicado: (2019)

Common NLRP3 inflammasome inhibitors and Covid-19: Divide and conquer
por: Batiha, Gaber El-Saber, et al.
Publicado: (2022)

Research Progress of Mitochondrial Mechanism in NLRP3 Inflammasome Activation and Exercise Regulation of NLRP3 Inflammasome
por: Zhang, Tan, et al.
Publicado: (2021)

The NLRP3 and NLRP1 inflammasomes are activated in Alzheimer’s disease
por: Saresella, Marina, et al.
Publicado: (2016)

The Role of Inflammasome-Dependent and Inflammasome-Independent NLRP3 in the Kidney
por: Kim, Yang Gyun, et al.
Publicado: (2019)

NLRP3 Inflammasome Pharmacological Inhibitors in Glycyrrhiza for NLRP3-Driven Diseases Treatment: Extinguishing the Fire of Inflammation
por: Wang, Zhilei, et al.
Publicado: (2022)

Activation and Inhibition of the NLRP3 Inflammasome by RNA Viruses
por: Choudhury, SK Mohiuddin, et al.
Publicado: (2021)

The role of the NLRP3 inflammasome in gout
por: Kingsbury, Sarah R, et al.
Publicado: (2011)

The Role of the NLRP3 Inflammasome in Fibrosis
por: Artlett, Carol M
Publicado: (2012)

NLRP3 Inflammasome and MS/EAE
por: Inoue, Makoto, et al.
Publicado: (2013)

NLRP3 Inflammasome and Pathobiology in AMD
por: Celkova, Lucia, et al.
Publicado: (2015)

Role of the NLRP3 inflammasome in cancer
por: Moossavi, Maryam, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_gong7ucfdlfmrsrfknpul7ahrd